Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation

Age and Ageing

Volumn 40, Issue 6, 2011, Pages 653-655

  Riva, Nicoletta ^a   Smith, Danielle E ^a   Lip, Gregory Y H ^a   Lane, Deirdre A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGING; ANTICOAGULANT THERAPY; BLEEDING RISK; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; EDITORIAL; ELDERLY CARE; FALL RISK; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; RISK REDUCTION; STROKE; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; HUMANS; PHYSICIANS;

EID: 80054895153     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afr128     Document Type: Editorial

References (22)

1. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.e4.
2. Pugh D, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011; 40: 675-83.
3. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56: 827-37.
4. Mazzaglia G, Filippi A, Alacqua M et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010; 103: 968-75.
5. Mant J, Hobbs FD, Fletcher K et al., on behalf of the BAFTA investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
6. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410-6.
7. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-105.
8. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006; 119: 607-15.
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-72.
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
11. Lipman T, Murtagh MJ, Thomson R. How researchconscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract 2004; 21: 290-8.
12. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-6.
13. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008; 39: 227-30.
14. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997; 45: 1060-5.
15. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006; 332: 141-5.
16. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323: 1218-22.
17. Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation-semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin. Age Ageing 2004; 33: 608-11.
18. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
19. Kirchhof P, Lip GY, Van Gelder IC et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2011; Jul 26 [Epub ahead of print].
20. Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 34-9.
21. Smith DE, Borg Xuereb C, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010; 10: 21.
22. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovasculardisease. Thromb Haemost 2010; 104: 49-60.